KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Non Operating Income (2017 - 2026)

Teva Pharmaceutical Industries filings provide 15 years of Non Operating Income readings, the most recent being -$216.0 million for Q1 2026.

  • On a quarterly basis, Non Operating Income rose 4.0% to -$216.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$925.0 million, a 3.24% increase, with the full-year FY2025 number at -$934.0 million, up 4.79% from a year prior.
  • Non Operating Income hit -$216.0 million in Q1 2026 for Teva Pharmaceutical Industries, up from -$220.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of -$211.0 million in Q2 2022 to a low of -$280.0 million in Q3 2023.
  • Median Non Operating Income over the past 5 years was -$249.0 million (2023), compared with a mean of -$244.4 million.
  • Biggest five-year swings in Non Operating Income: increased 22.99% in 2022 and later decreased 27.01% in 2023.
  • Teva Pharmaceutical Industries' Non Operating Income stood at -$245.0 million in 2022, then decreased by 1.63% to -$249.0 million in 2023, then grew by 12.45% to -$218.0 million in 2024, then decreased by 0.92% to -$220.0 million in 2025, then grew by 1.82% to -$216.0 million in 2026.
  • The last three reported values for Non Operating Income were -$216.0 million (Q1 2026), -$220.0 million (Q4 2025), and -$237.0 million (Q3 2025) per Business Quant data.